Mabion shares surge as FDA approves Polish biotech as US supplier

Mabion, a Polish biotech firm, received FDA approval to supply the US market, driving a continued rally in its shares. The approval marks a significant regulatory milestone, expanding its market access. Investors are reacting positively, but the long-term revenue impact remains uncertain.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works